ONCOLOGY / BASIC RESEARCH
Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) over-expression predicts poor prognosis in renal cell carcinoma
More details
Hide details
1
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2
Department of Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia
3
Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
4
Center of Excellence of Molecular and Cellular Medicine, Suez Canal University, Ismailia, Egypt
5
Botany Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
Submission date: 2018-04-19
Final revision date: 2018-06-06
Acceptance date: 2018-07-14
Online publication date: 2019-05-17
Publication date: 2021-07-16
Arch Med Sci 2021;17(4):1016-1027
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) is a newly identified cytoplasmic long non-coding RNA (lncRNA) implicated in cell longevity and apoptosis. We aimed in the current work for the first time to investigate the association of the expression profiles of LINC-ROR and three stem-related transcriptional factors with clinicopathological data and their impact on renal cell carcinoma (RCC) progression in a sample of RCC patients.
Material and methods:
Expression levels of LINC-ROR and stemness-related factors: SOX2, NANOG, and POU5F1 were detected in 60 formalin-fixed, paraffin-embedded tissues, and their paired adjacent non-cancer tissues (n = 60) by using real-time qRT-PCR analysis. Additionally, the expression profiles were compared with the available clinicopathological features.
Results:
The genes studied were markedly up-regulated in RCC (medians and interquartile ranges were 30.3 (1.84–235.5), 10.2 (1.84–53.9), 5.39 (0.94–23.5), and 12.5 (1.61–43.2) for LINC-ROR, SOX2, NANOG, and POU5F1, respectively) relative to paired non-cancer tissue. High expression levels were associated with poor prognosis in terms of tumour undifferentiation (for LINC-ROR, SOX2, and NANOG), lymph node infiltration (for SOX2), postoperative recurrence (for LINC-ROR and SOX2), and shorter overall survival (OS) and progression-free survival (for all genes studied). The best curve for OS prediction was constructed with LINC-ROR data (area under the receiver operating characteristic curve (AUC) = 0.804 at a cut-off value of 72.7, sensitivity 78.9%, and specificity 80.5%).
Conclusions:
Collectively, aberrant LINC-ROR and pluripotent gene expression may be recognised as prognostic markers for RCC. Future functional studies are highly recommended to validate the study findings.